Patent application number | Description | Published |
20100074903 | NOVEL ANTIBODY FORMULATION - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 03-25-2010 |
20110044977 | Subcutaneous anti-HER2 antibody formulations and uses thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 02-24-2011 |
20110158987 | NOVEL ANTIBODY FORMULATION - This invention relates to a pharmaceutical formulation of an antibody against Epidermal Growth Factor Receptor (EGFR), a process for the preparation and uses of the formulation. | 06-30-2011 |
20120321638 | FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 12-20-2012 |
20130209478 | FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 08-15-2013 |
20130216532 | Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof - The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided. | 08-22-2013 |
20130251725 | Anti-P-Selectin Antibody Formulation - The present invention relates to a stable liquid pharmaceutical formulation comprising 40 mg/ml to 200 mg/ml of an antibody against P-selectin; 0.01% to 0.1% of a poloxamer; 5 mM to 100 mM of a buffer; and 100 mM to 500 mM of at least one stabilizer; at a pH in the range from 4.5 to 7.0. | 09-26-2013 |
20140093512 | PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN AND A SUGAR SELECTED FROM SUCROSE AND TREHALOSE - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 04-03-2014 |